RestructuringApr 30, 2026, 05:08 PM
SCNX FY25 Revenue +216% to $431.6K; Net Loss $41.5M due to impairments
AI Summary
Scienture Holdings, Inc. (SCNX) reported a significant increase in revenues for the year ended December 31, 2025, reaching $431,609, up 216% from $136,643 in 2024, driven by initial sales of ARBLI™. Despite this, the company posted a net loss of $41,512,264, primarily due to $26,346,050 in non-cash impairment charges. The company completed a strategic realignment, divesting several legacy subsidiaries (SOSRx, Community Specialty Pharmacy, Alliance Pharma Solutions, Superlatus, Softell, IPS, Bonum Health entities) to focus on its specialty pharmaceutical subsidiary, Scienture LLC, and its products ARBLI™ and REZENOPY™. Management believes existing cash and growing revenues will fund operations for at least 12 months.
Key Highlights
- FY25 Revenue increased 216% to $431,609 from $136,643 in FY24.
- Gross profit surged 5420% to $331,482 in FY25 from $6,005 in FY24.
- Net loss from continuing operations was $41,512,264 in FY25, compared to $18,244,480 in FY24.
- Total operating expenses rose 192% to $42,922,324, primarily due to $26,346,050 in impairment losses.
- Cash and cash equivalents were $6,662,008 as of December 31, 2025.
- Company divested SOSRx, Community Specialty Pharmacy, Alliance Pharma Solutions, Superlatus, Softell, IPS, and Bonum Health entities.
- ARBLI™ (SCN-102) sales commenced in Q3 2025; REZENOPY™ anticipated in Q3 2026.
- Adjusted EBITDA was $(5,384,274) in FY25, down from $17,820,898 in FY24.